Chiesi Farmaceutici SpA - Company Profile
Powered by 
All the data and insights you need on Chiesi Farmaceutici SpA in one report.
$295
- Save hours of research time and resources with
our up-to-date Chiesi Farmaceutici SpA Strategy Report
- Understand Chiesi Farmaceutici SpA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
Chiesi Farmaceutici SpA (Chiesi) researches, develops, produces and commercializes novel medicines with a focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea of prematurity, respiratory distress syndrome, lipoprotein lipase deficiency (LPLD), limbal stem cell deficiency (LSCD) and inflammatory bowel diseases, among others. The company operates production sites in Parma, Italy; Blois, France; and Santana De Parnaiba, Brazil; and conducts research and development activities in its R&D center in Parma and at laboratories in Paris (France), Chippenham (the UK), Cary (the US) and Lidingo (Sweden). Chiesi is headquartered in Parma, Emilia-Romagna, Italy.
Headquarters
Italy
Address
Via Palermo, 26/A, Parma, Emilia-Romagna, 43122
Website
www.chiesi.com
Telephone
39 0521 2791
No of Employees
6,500
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$787.6M
Chiesi Farmaceutici SpA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Respiratory | Atimos |
| Rare Diseases | Atem |
| Neonatology | Becloneb |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company entered into an agreement with Oak Hill Bio to create, produce, and market OHB-607, a potentially revolutionary new-born treatment. |
| 2023 | Contracts/Agreements | In August, Chiesi Global Rare Diseases entered into a co-development agreement with Aliada Therapeutics to develop a novel blood-brain barrier-crossing platform technology to address challenging disease areas. |
| 2023 | Contracts/Agreements | In July, the company entered into an agreement with Kwangdong Pharmaceutical to secure exclusive sales and distribution rights in the domestic market. |
Competitor Comparison
| Key Parameters | Chiesi Farmaceutici SpA | Recordati SpA | Cosmo Pharmaceuticals NV | Newron Pharmaceuticals SpA | FB Health SpA |
|---|---|---|---|---|---|
| Headquarters | Italy | Italy | Ireland | Italy | Italy |
| City | Parma | Milano | Dublin | Bresso | Ascoli Piceno |
| State/Province | Emilia-Romagna | - | - | - | Marche |
| No. of Employees | 6,500 | 4,455 | 325 | 23 | - |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Alessandro Chiesi | Chairman | Executive Board | 2023 | - |
| Maria Paola Chiesi | Vice Chairman | Executive Board | 2023 | - |
| Giuseppe Accogli | Chief Executive Officer - Group | Senior Management | 2023 | - |
| Alberto Chiesi | President; Director | Executive Board | - | - |
| Giacomo Chiesi | Director; Head-Global Rare Diseases | Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward